EUCTR2021-000058-24-NL进行中（未招募）1 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis. - Connect&Go
Erasmus MC Cancer Institute0 个研究点目标入组 390 人开始时间: 2021年5月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age =18 years
- •-Able and willing to give written informed consent
- •-Planned treatment with nivolumab or pembrolizumab monotherapy (with or without prior treatment with Nivolumab/Ipilimumab) for any EMA
- •approved indication and with any dose
- •-Adequate Dutch language proficiency (at least proficiency level C1)
- •-At least 3 prior cycles of nivolumab or pembrolizumab in medical history
- •-At least 4 remaining cycles of nivolumab or pembrolizumab monotherapy after inclusion in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 312
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 78
排除标准
- •Prior hypersensitivity reactions to nivolumab or pembrolizumab (any grade).
研究者
相似试验
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
招募中
4 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
尚未招募
Unknown
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.JPRN-UMIN000050723Kobe University200
已完成
不适用
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanomaJPRN-UMIN000026925Kochi University, Kochi Medical School5
进行中（未招募）
1 期
Pre-operative immunotherapy in early-stage colon cancersEUCTR2016-002940-17-NLAntoni van Leeuwenhoek155